Volume 18, Issue 8, Pages (August 2011)

Slides:



Advertisements
Similar presentations
John Hines, Michael Groll, Margaret Fahnestock, Craig M. Crews 
Advertisements

Mahadeb Pal, Alfred S. Ponticelli, Donal S. Luse  Molecular Cell 
Volume 22, Issue 7, Pages (July 2015)
Volume 19, Issue 4, Pages (April 2012)
The Small-Molecule Iron Transport Inhibitor Ferristatin/NSC Promotes Degradation of the Transferrin Receptor  Lior Horonchik, Marianne Wessling-Resnick 
Volume 67, Issue 1, Pages e3 (July 2017)
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing
Volume 10, Issue 5, Pages (November 2002)
Kristina M. Johnson, Michael Carey  Current Biology 
Volume 3, Issue 1, Pages (January 1999)
Volume 19, Issue 4, Pages (April 2012)
Volume 38, Issue 1, Pages (April 2010)
Yan Jiang, Mingyi Liu, Charlotte A. Spencer, David H. Price 
Volume 22, Issue 7, Pages (July 2015)
Origin recognition complex binding to a metazoan replication origin
Transcriptional Activators Enhance Polyadenylation of mRNA Precursors
Volume 139, Issue 5, Pages (November 2009)
The Initial Response of a Eukaryotic Replisome to DNA Damage
John Hines, Michael Groll, Margaret Fahnestock, Craig M. Crews 
Discovery of Widespread GTP-Binding Motifs in Genomic DNA and RNA
Volume 12, Issue 3, Pages (March 2005)
Transcriptional Activators Stimulate DNA Repair
Tonko Buterin, Christoph Meyer, Bernd Giese, Hanspeter Naegeli 
SUMO Promotes HDAC-Mediated Transcriptional Repression
The Rpd3 Core Complex Is a Chromatin Stabilization Module
Volume 50, Issue 3, Pages (May 2013)
Volume 21, Issue 3, Pages (March 2014)
Rapid identification of efficient target cleavage sites using a hammerhead ribozyme library in an iterative manner  Wei-Hua Pan, Ping Xin, Vuong Bui,
Volume 22, Issue 3, Pages (March 2015)
Mu Transpososome Architecture Ensures that Unfolding by ClpX or Proteolysis by ClpXP Remodels but Does Not Destroy the Complex  Briana M. Burton, Tania.
Transcriptional Fidelity and Proofreading by RNA Polymerase II
Xinyang Zhao, P.Shannon Pendergrast, Nouria Hernandez  Molecular Cell 
Volume 17, Issue 1, Pages (January 2010)
Hideaki Saeki, Jesper Q. Svejstrup  Molecular Cell 
Volume 36, Issue 4, Pages (November 2009)
Vidya Subramanian, Pascal Ducept, Robert M. Williams, Karolin Luger 
Volume 19, Issue 7, Pages (July 2012)
Nature of the Nucleosomal Barrier to RNA Polymerase II
Volume 24, Issue 3, Pages (November 2006)
Volume 1, Issue 1, Pages (December 1997)
Volume 47, Issue 4, Pages (August 2012)
Volume 13, Issue 3, Pages (March 2006)
Joshua C. Black, Janet E. Choi, Sarah R. Lombardo, Michael Carey 
Volume 39, Issue 3, Pages (August 2010)
Frpo: A Novel Single-Stranded DNA Promoter for Transcription and for Primer RNA Synthesis of DNA Replication  Hisao Masai, Ken-ichi Arai  Cell  Volume.
Volume 12, Issue 1, Pages (January 2005)
Ken-ichi Yoshioka, Yoshiko Yoshioka, Peggy Hsieh  Molecular Cell 
The Mammalian RNA Polymerase II C-Terminal Domain Interacts with RNA to Suppress Transcription-Coupled 3′ End Formation  Syuzo Kaneko, James L. Manley 
Volume 8, Issue 11, Pages (November 2001)
Volume 25, Issue 21, Pages (November 2015)
Volume 51, Issue 2, Pages (July 2013)
A Movie of RNA Polymerase II Transcription
Inhibitor Mediated Protein Degradation
Brh2 Promotes a Template-Switching Reaction Enabling Recombinational Bypass of Lesions during DNA Synthesis  Nayef Mazloum, William K. Holloman  Molecular.
Volume 17, Issue 12, Pages (December 2010)
Volume 24, Issue 3, Pages (November 2006)
Volume 12, Issue 11, Pages (November 2005)
Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing
Nbs1 Converts the Human Mre11/Rad50 Nuclease Complex into an Endo/Exonuclease Machine Specific for Protein-DNA Adducts  Rajashree A. Deshpande, Ji-Hoon.
Volume 21, Issue 2, Pages (February 2014)
RNA Polymerase II Activity of Type 3 Pol III Promoters
Volume 22, Issue 11, Pages (November 2015)
Yan Jiang, Mingyi Liu, Charlotte A. Spencer, David H. Price 
Volume 14, Issue 2, Pages (April 2004)
Synthetic Chromatin Acylation by an Artificial Catalyst System
Transcriptional Regulation by p53 through Intrinsic DNA/Chromatin Binding and Site- Directed Cofactor Recruitment  Joaquin M Espinosa, Beverly M Emerson 
Michael J. McIlwraith, Stephen C. West  Molecular Cell 
Huan Chen, Michael Lisby, Lorraine S. Symington  Molecular Cell 
Functional Coupling of Capping and Transcription of mRNA
Volume 3, Issue 1, Pages (January 1999)
Presentation transcript:

Volume 18, Issue 8, Pages 988-999 (August 2011) XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids  Sascha Feuerhahn, Christophe Giraudon, Marta Martínez-Díez, Juan A. Bueren-Calabuig, Carlos M. Galmarini, Federico Gago, Jean- Marc Egly  Chemistry & Biology  Volume 18, Issue 8, Pages 988-999 (August 2011) DOI: 10.1016/j.chembiol.2011.06.007 Copyright © 2011 Elsevier Ltd Terms and Conditions

Chemistry & Biology 2011 18, 988-999DOI: (10. 1016/j. chembiol. 2011 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Cytotoxic Effects of Trabectedin and Zalypsis Structures of trabectedin (A) and Zalypsis (B). (C) Real-time PCR analysis of RARβ2 induction by t-RA from HeLa cells pretreated with different concentrations of trabectedin (dark gray) and Zalypsis (light gray). The fold activation (noninduced versus induced) is shown, and RARβ2 mRNA was normalized to GAPDH mRNA levels. Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 DNase I Footprinting Assays on the SV40 Promoter and on DNA Templates Containing a Unique Drug-Binding Site (A) The 32P-labeled and immobilized SV40 promoter was incubated with increasing amounts of either HeLa NE or trabectedin before being digested by DNase I. The Sp1-binding sites are shown at the right of the gel. (B) Different rounds of incubation of either HeLa NE or trabectedin, as indicated at the top of the panel, were performed on the bead-immobilized SV40 promoter-containing DNA followed by DNase I treatment. The AS/CGG (C) or OS/CCGh (D) was incubated with increasing drug concentrations and treated with DNase I. The positions of the HS (A and B) or the protected nucleotides (C and D) are indicated (nb: for C and D the G0 is the guanine that is covalently bonded to the drug). See also Figure S1. Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Effects of Trabectedin and Zalypsis on Transcription (A) Scheme of the 5′ end-immobilized DNA containing the unique binding site 5′-CGG-3′. The drug-modified guanine (G) is positioned at +113 bp of the transcription start site (+1) either on the CGG/TS or the CGG/NTS. (B) The DNA template was incubated with amounts of drug as indicated. Quantification of the +96 and +99 nt long transcripts was performed using the ImageJ software. The CGG/TS (C) and the CGG/NTS (D) DNA templates were transcribed in the presence of NTPs except GTP, leading to RNA pol II arrest at the end of the G-less-cassette. After incubation with increasing amounts of trabectedin and Zalypsis and washing off the unbound drug, transcription was resumed in the presence of all NTPs including GTP. The RNA transcripts were analyzed on a 5% denaturing urea gel, and quantifications of the full-length transcripts (FLT, +223 bp) were performed. Trabectedin or Zalypsis-mediated stops were detected close to the 5′-CGG-3′ containing region (+113 nt). The drug-induced RNA pol II arrests are indicated in brackets on the sequence on the right of each gel. Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Trabectedin- and Zalypsis-Dependent Effects on DNA Incision (A) Characterization of the incision on the AS/CGG and the OS/CCGh pretreated with trabectedin and incubated with NER factors in the presence or absence of XPG and XPF. XPF-dependent incision on either the AS/CGG or the OS/CCGh in the presence or absence of either trabectedin (B and C) or Zalypsis (D and E). (F) RPA-mediated effect on the trabectedin (right panel)- and Zalypsis (left panel)-dependent incision using the AS/CGG and the OS/CCGh substrates. See also Figure S2. Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 5 Trabectedin and Zalypsis Induce DNA Breaks In Vivo (A) Representative images of damaged DNA in the comet assay in untreated and trabectedin-treated (for 12 hr) HeLa cells. HeLa siCtrl and HeLa siXPF cells were analyzed through comet assay followed by exposure to (B) trabectedin and (C) Zalypsis at 10 and 100 nM during 15 hr. Cells were treated, washed with PBS, detached mechanically, and included in low melting point agarose. After lysis, cells were subjected to electrophoresis, and the comets were stained with SYBR Green. DNA quantitation in the comets was performed with TriTek CometScore Freeware version 1.5 (p < 0.001). Pictures were taken with a Leica DM IRM fluorescence microscope equipped with a DFC 340 FX digital camera (Leica, Wetzlar, Germany). A minimum of 200 cells was analyzed, and the experiments were repeated in duplicate. The Mann-Whitney U test was used for the statistical analysis. See also Figures S3 and S4. Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 6 Impact of Trabectedin and Zalypsis on DNA Incision and Transcription Processes Trabectedin (A) and Zalypsis (B) stimulate an XPF-dependent incision on the OS/CCGh, i.e., the strand opposite to that harboring the drug adducts. Trabectedin (C) and Zalypsis (D) block RNA pol II progression when the drug is located either on the TS or the NTS. Only the complex structure containing the longest possible RNA transcript is represented for each drug. The schematic representation of RNA pol II is based on Figure 4 from Cramer (2004). Chemistry & Biology 2011 18, 988-999DOI: (10.1016/j.chembiol.2011.06.007) Copyright © 2011 Elsevier Ltd Terms and Conditions